Close menu




March 8th, 2021 | 10:30 CET

Everfuel, Revez, Merck KGaA - Profiting from the future of the Internet!

  • Software
Photo credits: pixabay.com

The new, normal world will change in all industries. It is moving away from offline and stationary and moving towards more hybrid and online solutions. Stationary retail will inevitably start the hybrid Click & Collect program from tomorrow. The home office move requires more features such as sophisticated video conferencing systems, but this also increases the need for better security online. A pioneer in these business areas combines all the needs of the digital age in one hub.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: DK0061414711 , SGXE83751573 , DE0006599905

Table of contents:


    Revez - The pioneer of Internet 4.0

    Double-digit revenue growth and a gross margin of close to 60% are what Singapore-based technology service provider Revez has been delivering since 2010. In the process, the debt-free market leader in the Asia-Pacific region for interactive multimedia, information and communications solutions is growing in line with the requirements of its more than 100 customers, who come from all industries and both the private and public sectors. Global top names such as Microsoft, PayPal, Subway, as well as museums and theme parks for which virtual tours are programmed, are among them. In total, Revez covers information and communications technology (ICT), deep tech in artificial intelligence (AI) and Internet of Things (IoT), industrial automation, cybersecurity and MICE support through five subsidiaries. While the companies are legally separate, internally, they form an eco-system designed to promote cross-selling, maximize economies of scale and allocate resources effectively.

    The Corona pandemic, which pushed humanity further into the online world, was used to further future-proof existing applications for clientele. The expansion of virtual meeting rooms was accelerated, as were digital media offerings and solutions relating to automation in the industry. In addition, new next-generation cybersecurity solutions based on artificial intelligence were developed. Revez management also sees an acceleration of virtual tourism and the expansion of hybrid platforms on the enterprise side in the coming years. Public services such as museums and libraries increasingly recognize the benefits of virtual tours. A rosy future should lie ahead for the market leader, which is currently doing more business in Asia but plans to acquire globally in the future. Revez shares are traded on the Singapore stock exchange as well as in Germany. The stock market value is currently around EUR 25.01 million.

    Merck KGaA - Strongly positioned

    Brilliant figures, an even better outlook and a strong positioning - this is how one can describe the current events surrounding the German chemical and pharmaceutical Company Merck KGaA. In the Corona year 2020, sales increased by 8.6% to EUR 17.5 billion. Adjusted operating profit grew 18.6% to EUR 5.2 billion, which also meant the Company achieved its full-year targets. Fourth-quarter earnings of EUR 1.2 billion were just below analysts' estimates of EUR 1.24 billion. Earnings per share increased by EUR 6.70. The strong figures were due to the Life Science segment, which pulled along the other divisions, such as the weakly performing fertility treatments business. As a result, the dividend for shareholders will be increased by EUR 0.10 to now EUR 1.40.

    The year 2021 also looks rosy for the Darmstadt-based Company. It is one of the most important suppliers to the pharmaceutical and biotechnology industries and, as in the previous year, is benefiting from global research vaccines against the Coronavirus. Taken together, the Group is involved in a total of 50 vaccine projects. CEO Stefan Oschmann expects continued strong organic growth due to unprecedented demand. EBITDA is also expected to grow in a high single-digit to low double-digit percentage range. In addition to life science, the Company is also on track with new drugs such as the cancer immunotherapy Bavencio and the multiple sclerosis drug Mavenclad. The share is currently correcting from its all-time high of EUR 149.94. Good support is at EUR 120. In the long term, the Darmstadt-based Company is broadly and strongly positioned.

    Everfuel - What is next?

    The correction in hydrogen stocks continues. The subsidiary Everfuel, which emerged from the spin-off of Nel ASA, has run out of steam. The Danes fell from the high in January of EUR 18.30 to currently EUR 7.76. Nevertheless, the market capitalization still amounts to an impressive EUR 608.0 million. Now the stock market newcomer announced their figures. Annual sales in 2020 amounted to EUR 1.05 million. As expected, EBITDA was in the red at minus EUR 800,000.

    Sales, on the other hand, are expected to rise sharply starting next year. The goal of becoming a leading hydrogen company is to be achieved through inorganic growth. With a significantly oversubscribed capital increase and a cash balance of just under EUR 24 million, the Company also intends to push ahead with its market leadership in Scandinavia and expand its filling station network. Despite the more than 50% share price correction, Everfuel's share price still has a great deal of future potential. Because the pure free float amounts to a maximum of 5%, we see better opportunities with other fallen stocks.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Fabian Lorenz on May 6th, 2022 | 11:49 CEST

    TeamViewer, Nel, mm2 Asia: Analysts see upside potential

    • entertainment
    • Hydrogen
    • Software

    The US Federal Reserve raised key interest rates by 0.5 percentage points on Wednesday to counteract rapidly rising inflation. After falling sharply in the run-up to the move, share prices worldwide subsequently rallied again. Yesterday, the DAX was back above 14,000 points. Analysts also commented positively on selected shares. For example, TeamViewer's quarterly figures were a positive surprise and analysts see significant upside potential. Goldman Sachs even sees a price potential of over 50% for Nel, and the hydrogen specialist has also landed the next order. However, more has to come. And in the case of the Asian media and technology company mm2 Asia, analysts see even more than 100% share price potential - partly due to the NFT marketplace. Elon Musk has now also discovered the hype surrounding NFTs for himself.

    Read

    Commented by André Will-Laudien on April 6th, 2022 | 10:46 CEST

    Siemens Healthineers, Perimeter Medical, Siemens, SAP - After BioNTech, now the push for MedTech shares!

    • medtech
    • Biotechnology
    • Software

    The most significant positive share price developments in the last 12 months occurred in the biotech sector, especially among vaccine manufacturers such as BioNTech and Moderna. The stock market overlooked that pandemics, and the fight against them, offer short-term profit opportunities. The great battle against widespread diseases such as cardiovascular disease, cancer or other previously incurable indications progresses steadily. Their diagnosis and treatment require many types of technology, devices, processes, analysis tools, and intelligent software. Some methods certainly deserve the attribute "disruptive technology". We take a look at some blockbusters in the MedTech segment.

    Read

    Commented by Carsten Mainitz on March 9th, 2022 | 12:14 CET

    Kleos Space, Palantir, Deutsche Bank - Data like gold

    • Space
    • Software

    The nervousness caused by the dramatic situation in Ukraine is also spreading to the global capital markets. Germany's leading index, the DAX, fell to a new low for the year of 12,431.50 points. By contrast, gold, the crisis currency, was bullish and put an initial exclamation mark above the USD 2,000 per ounce mark. Data providers such as Kleos Space and Palantir, whose Gotham software provides analyses for the US armed forces, among others, are also in demand.

    Read